Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Monitor Malta.
Press releases published on August 20, 2025
Ascentage Pharma Reports 2025 Interim Unaudited Six Months Financial Results and Business Updates
Product sales from Olverembatinib in the first half of 2025 increased 93% year-over-year to US$30.3 million (RMB217.4 million), primarily attributable to the expansion of NRDL coverage Commenced commercial sales of Lisaftoclax in China, following approval …
Global Enzymes Market Set to Reach $20.4 Billion by 2029 | Asia-Pacific Emerges as a Hotspot
Delray Beach, FL, Aug. 20, 2025 (GLOBE NEWSWIRE) -- According to MarketsandMarkets, the global enzymes market is experiencing robust growth, driven by innovations in biotechnology, increasing demand in biopharmaceutical production, and rising environmental …
Larkspur Biosciences Announces Discovery of LRK-4189, a First-in-Class Degrader of the Lipid Kinase PIP4K2C, for the Treatment of Microsatellite Stable (MSS) Colorectal Cancer at the ACS Fall 2025 Meeting
CAMBRIDGE, Mass., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Larkspur Biosciences, a company pioneering a new wave in cancer therapy that destroys tumors by targeting cancer cell fitness, today announced the discovery of LRK-4189, a first-in-class degrader of the …
BioAge Labs to Present at Upcoming Investor Conferences
EMERYVILLE, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of human …
Olema Oncology to Participate in Upcoming Investor Conferences
SAN FRANCISCO, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for …
Onco360® Has Been Selected as a Specialty Pharmacy Partner for HERNEXEOS® (zongertinib)
LOUISVILLE, K.Y., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected as a pharmacy partner by Boehringer Ingelheim for Hernexeos® (Zongertinib). The Food and Drug Administration approved …
Outset Medical to Present at the 23rd Annual Morgan Stanley Global Healthcare Conference
SAN JOSE, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that management will …
Sana Biotechnology Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares
SEATTLE, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (Nasdaq: SANA) (“Sana”), a company focused on changing the possible for patients through engineered cells, today announced that it has closed the sale of 3,358,208 shares of its common …
NurExone Biologic Announces Preclinical Evidence of Structural Repair in Injured Spinal Cord Tissue following ExoPTEN Treatment
TORONTO and HAIFA, Israel, Aug. 20, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) is pleased to announce new preclinical imaging results providing anatomical evidence consistent with …
Rhythm Pharmaceuticals Announces FDA Acceptance of sNDA for Setmelanotide in Acquired Hypothalamic Obesity
– U.S. Food and Drug Administration accepts sNDA for filing with priority review; sets PDUFA goal date of December 20, 2025 -- – European Medicines Agency accepts and validates submission for Type II variation MAA for setmelanotide to treat acquired …
Invivyd Announces Proposed Public Offering of Common Stock
WALTHAM, Mass., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Invivyd) (Nasdaq: IVVD) today announced that it has commenced an underwritten public offering of shares of its common stock. In addition, Invivyd intends to grant the underwriters an option …
Zealand Pharma major shareholder announcement: Van Herk Investments B.V.
Company announcement – No. 19 / 2025 Zealand Pharma major shareholder announcement: Van Herk Investments B.V. Copenhagen, Denmark, August 20, 2025 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the …
APIX Biosciences NV announces new advances in Honeybee Nutrition
WINGENE, Belgium, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Belgian agri-technology company APIX Biosciences NV, active in Europe and the United States, proudly announces the publication in Nature, by APIX Biosciences’ Scientific Founder Prof. Geraldine Wright and …
2030 financial targets announced: Organic sales growth acceleration, margin expansion and ROIC improvement
COPENHAGEN, Denmark - August 20, 2025. Novonesis today announces its ‘GROW’ strategy and long-term targets for the strategy period until 2030 focusing on an acceleration of the core business and significant re-investments to secure long-term growth. By …
Global Big Data in Healthcare Market is Predicted to Cross the USD 330 Billion Mark by 2032 | DelveInsight
New York, USA, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Global Big Data in Healthcare Market is Predicted to Cross the USD 330 Billion Mark by 2032 | DelveInsight The demand for big data in healthcare is growing rapidly, fueled by the rising incidence of chronic …
Merkel Cell Carcinoma Market Set for Rapid Growth in the Coming 10 Years Across the 7MM | DelveInsight
New York, USA, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Merkel Cell Carcinoma Market Set for Rapid Growth in the Coming 10 Years Across the 7MM | DelveInsight The market size of Merkel cell carcinoma in the 7MM is expected to increase during the forecast period ( …
King Faisal Specialist Hospital Provides Nearly 300,000 Virtual Consultations in 2024
RIYADH, Saudi Arabia, Aug. 20, 2025 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital and Research Centre (KFSHRC) delivered 293,381 virtual clinic visits in 2024, a 58.2% increase from the previous year. The growth highlights how telehealth has become …
OSE Immunotherapeutics Appoints Thomas Gidoin as Chief Financial Officer
NANTES, France, August 20, 2025 – 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today announced the appointment of Thomas Gidoin as Chief Financial Officer. Thomas joins the Executive Committee, bringing over 15 years of deep …
OSE Immunotherapeutics nomme Thomas Gidoin au poste de Directeur Financier
NANTES, France - 20 août 2025, 18 h 00 – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), annonce aujourd’hui la nomination de Thomas Gidoin au poste de Directeur Financier. Thomas rejoint le Comité Exécutif, apportant à la Société plus de 15 …
BioAdaptives’ MyndMed™ Receives Full Clearance from TruShield™, Meeting UFC and WADA Standards for Athlete Safety
LAS VEGAS, Aug. 20, 2025 (GLOBE NEWSWIRE) -- via IBN – BioAdaptives, Inc. (OTCMKTS: BDPT), a leader in natural health and performance supplements, today announced that its flagship nootropic formula, MyndMed™, has been officially certified clean by …